Engineering the Therapeutics of the Future

Co-Located with Molecular Med TRI-CON Asia

May 28-31, 2013
Marina Bay Sands, Singapore

Co-Located Bio-IT World Asia

 

Day 1 | Day 2 | Download Brochure 

Friday, May 31

8:30 Morning Coffee


» KEYNOTE SESSION 

8:50 Chairperson’s Remarks

Stanley Y. Shaw, M.D., Ph.D., Co-Director, Center for Assessment Technology and Continuous Health (CATCH), Massachusetts General Hospital (MGH); Co-Director of Chemical Biology, MGH Center for Systems Biology; Assistant Professor, Harvard Medical School

 

9:00 Genome 10K: A Genomic Zoo of 10,000 Vertebrates

Byrappa VenkateshProf. B. Venkatesh, Ph.D., Research Director, Institute of Molecular and Cell Biology (IMCB), A*STAR

Genome 10K is an ambitious project which aims to catalogue genome sequences of 10,000 vertebrates across mammals, birds, non-avian reptiles, amphibians and fishes. These sequences would be a valuable resource to gain insights into the genetic basis of morphological diversity, adaptation and response to environmental changes. The project would also help in formulating guidelines for assessment, monitoring and conservation of biodiversity. I will be discussing the strategy, progress and challenges of the Genome 10K project.

 

9:45 The Human Protein Atlas - An Update with Emphasis on the Contribution of Indian Surgical Pathology

Sanjay NavaniSanjay Navani, M.D., Surgical Pathologist and Immunohistochemist, LAB SURGPATH; Site Director, The Human Protein Atlas (HPA) Project

The Human Protein Atlas (HPA) program (www.proteinatlas.org) is an international program that has been set up to allow for a systematic exploration of the human proteome using Antibody-Based Proteomics. This is accomplished by combining high-throughput generation of affinity-purified (mono-specific) antibodies with protein profiling in a multitude of tissues/cell types assembled in tissue microarrays. A brief overview with a current update emphasizing the Indian contribution is provided.

 

10:30 Coffee Break in the Exhibit Hall with Poster Viewing


NGS FOR DIAGNOSTICS 

11:20 Chairperson's Remarks

Sanjay K. Kakkar, MBBS, MSc. M.P.H., Chairman and Founder, Jai Medica Pvt. Ltd. (Jai Health)

11:30 Introducing Deep Sequencing into Clinical Workflows

Richie SoongRichie Soong, Ph.D., Research Associate Professor and Senior Principal Investigator, Center for Translational Medicine, National University of Singapore

Deep sequencing promises much to clinical diagnostics with its digital output, speed, and depth and breadth of coverage. However, to realize this promise, both technical and cultural issues need to be addressed. Technical issues include the handling of low level variants and bioinformatics. Cultural issues include the development of expertise and change management. Our efforts to address these issues will be covered.

12:00 From Sanger to NGS : Making the Transition in the Clinical Laboratory

Andrew FellowesAndrew Fellowes, Ph.D., FHGSA, FFSc(RCPA), Scientist in Charge, Molecular Pathology Diagnostic Development, Peter MacCallum Cancer Centre

Multiplex amplicon generation combined with parallel sequencing allows clinical laboratories to consolidate their menu of Sanger-based assays into a small number of targeted gene panels. Parallel sequencing of amplicons requires careful optimization and continuous quality control compared to Sanger sequencing, however this approach can improve clinical sensitivity while reducing costs, limiting variation and reducing turnaround times. Obstacles encountered and overcome during the development and introduction of a familial cancer panel based on parallel sequencing of targeted amplicons will be described.

12:30 Lunch on Your Own


PERSONALIZED DIAGNOSTICS 

13:45 Chairperson’s Remarks

Peter PackPeter Pack, Ph.D., Owner and Senior Consultant, Science2Biz; Co-founder and Former CEO of mtm laboratories, Heidelberg (now mtm Roche); Former Managing Director of LGC Standards, London


 


13:50 Caveats of Personalized Medicine

Pauline NgPauline Ng, Ph.D., Group Leader, Computational & Mathematical Biology, Genome Institute of Singapore

As new technologies such as next-gen sequencing are integrated into hospitals, what are the factors that a patient takes into consideration when making medical choices? I will present my group’s bioinformatic  tools that provide useful and high-confidence information to patients so that both clinicians and patients can benefit in terms of informed decision-making.

 

14:20  Shortening the Diagnostic Odyssey

Vamsi VeeramachaneniVamsi Veeramachaneni, Ph.D., Vice President, Bioinformatics, Strand Life Sciences

This talk will describe our experiences at Strand in using genomic sequencing and bioinformatics techniques to shorten the odyssey to diagnosis for rare disease cases. Inspired by these cases, we are building  integrated software that combines curated literature content, bioinformatics databases, and various algorithms and user interfaces to substantially compress time taken and make it easier for clinicians to determine likely candidate variants in a Diagnostic Odyssey.
 

14:40 Refreshment Break in the Exhibit Hall with Poster Viewing

15:10 India’s Cardiovascular Epidemic – Prevention through Innovation

Sanjay KakkarSanjay K. Kakkar, MBBS, MSc, M.P.H., Chairman and Founder, Jai Medica Pvt. Ltd. (Jai Health)

This talk will briefly review the health, social and economic burden of cardiovascular disease (CVD) in India. It will then outline the challenge of risk assessment using conventional risk factors and summarize the novel approaches to improve early detection of CVD. The last part of this talk will explore how genetic markers can be used in conjunction with conventional risk factors as a basis for personalized preventive strategies and describe the JaiHeart™ test.

15:30 Molecular Painting: Broad-Ranging Applications Including Diagnostics

John DangerfieldJohn Dangerfield, Ph.D., Managing Director, Anovasia Pte Ltd

Anovasia has commercially developed a membrane surface modification technique based on the glycosylphosphatidylinositol (GPI-anchor) molecule. Termed Molecular Painting, this can be used to tag or label the surface of any biomembrane such as cells, enveloped viruses, virus-based or virus-like vector particles, liposomes or exosomes. Applications in basic and applied research, diagnostics, protein/gene delivery, drug delivery, vaccine development and cell therapy will be discussed with a focus on targeting of biomarkers for molecular diagnostics whereby some recent data will be presented.

15:50 Challenges and Opportunities of Starting Molecular Diagnostic Business in Asia

Alex Thian, CEO, AIT Biotech

16:10 Panel Discussion: How to Position Novel Molecular Diagnostics  in Medical Practice

Moderator:

Peter Pack, Ph.D., Owner and Senior Consultant, Science2Biz; Co-founder and Former CEO of mtm laboratories, Heidelberg (now mtm Roche); Former Managing Director of LGC Standards, London

Panelist:

Sanjay K. Kakkar, MBBS, MSc. M.P.H., Chairman and Founder, Jai Medica Pvt. Ltd. (Jai Health)

Richie Soong, Ph.D., Research Associate Professor and Senior Principal Investigator, Center for Translational Medicine, National University of Singapore

Toshihisa Ishikawa, Ph.D., Professor of Biochemistry, Molecular Biology and Pharmacogenomics, Omics Science Center, RIKEN Yokohama Institute

 

16:40 End of Conference



Day 1 | Day 2 | Download Brochure